5.23.'22

Capital investments in Swiss biotech companies reached the second-best amount ever with CHF 3.33 billion in 2021. Investment in Research and Development (R&D) during the pandemic grew to a record high of CHF 2.56 billion. The Swiss biotech industry generated sales of CHF 6.7 billion in 2021, compared to CHF 4.9 billion in 2020. This significant increase is mainly due to an increase in product sales, positive one-off effects from cooperation and license agreements, and a generally positive development attributed to the product pipeline, which led to that the approvals will continue at a very high level in 2021.

Swiss Biotech Report HP　 → Swiss Biotech Report

Swiss Biotech Report 2022 Web (PDF) 　→